Novartis Stops Drug Marketing Amid Safety Concerns

Law360, New York (March 30, 2007, 12:00 AM EDT) -- Nudged by the U.S. Food and Drug Administration, Switzerland’s Novartis on Friday agreed to stop marketing the drug Zelnorm amid concerns the drug could trigger serious heart problems.

The FDA asked Novartis to pull its marketing after the drug maker submitted a research study showing that the risk of serious cardiovascular adverse events such as heart attacks and strokes are associated with use of Zelnorm is higher than with placebo treatment.

In an analysis of 11,600 patients treated with Zelnorm and over 7000 patients treated with...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.